0001193125-19-245346.txt : 20190916 0001193125-19-245346.hdr.sgml : 20190916 20190916070903 ACCESSION NUMBER: 0001193125-19-245346 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20190914 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20190916 DATE AS OF CHANGE: 20190916 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc. CENTRAL INDEX KEY: 0001503802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263931704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36167 FILM NUMBER: 191093736 BUSINESS ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 BUSINESS PHONE: 617-658-0600 MAIL ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 8-K 1 d804595d8k.htm 8-K 8-K
false 0001503802 0001503802 2019-09-14 2019-09-14

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 14, 2019

 

Karyopharm Therapeutics Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

  

001-36167

 

26-3931704

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

85 Wells Avenue, 2nd Floor

Newton, Massachusetts

  

02459

(Address of Principal Executive Offices)

  

(Zip Code)

Registrant’s telephone number, including area code: (617) 658-0600

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value

  

KPTI

  

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

Item 1.01.    Entry into a Material Definitive Agreement.

On September 14, 2019, Karyopharm Therapeutics Inc. (the “Company”) entered into a Revenue Interest Financing Agreement (the “Agreement”) with HealthCare Royalty Partners III, L.P. and HealthCare Royalty Partners IV, L.P (the “Investors”), affiliates of HealthCare Royalty Management, LLC, as agent for the Investors (the “Investor Representative”). Pursuant to the Agreement, the Investors will pay, subject to customary closing conditions, $75.0 million (the “First Investment Amount”), less certain transaction expenses, to the Company at the initial closing, which is expected to occur on September 27, 2019. The Company will also be entitled to receive an additional $75.0 million (the “Second Investment Amount”, and together with the First Investment Amount, the “Investment Amount”) upon the achievement of future regulatory and commercial milestones and subject to the approval of both parties and customary closing conditions.

As consideration for such payments, the Investors will receive payments equal to a percentage (the “Applicable Tiered Percentage”) of net revenues of XPOVIOTM (selinexor) and any other future products of the Company, including worldwide net product sales and upfront payments, milestones and royalties (the “Revenue Interests”). The Applicable Tiered Percentage will initially be 7% on portions of annual net revenues up to $250 million, 2.625% on portions of annual net revenues between $250 million and $500 million and 1% on portions of annual net revenues exceeding $500 million. The Applicable Tiered Percentage is also subject to reduction in the future if a target based on cumulative U.S. net sales is met. If the Investors have not received 0.65x of the Investment Amount by December 31, 2022 or 1.00x of the Investment Amount by December 31, 2024, the Company must make a cash payment sufficient to gross the Investors up to such minimum amounts. The Investors’ rights to receive the Revenue Interests shall terminate on the date on which the Investors have received payments of 185% of the Investment Amount (the “Hard Cap”), unless the Agreement is earlier terminated. If the Investors have not received payments equal to the Hard Cap by the twelve-year anniversary of the initial closing date, the Company shall pay an amount equal to the Investment Amount plus a specific annual rate of return less payments previously received. The net revenue thresholds described above are not to be interpreted as financial guidance or projections for future net revenues of the Company.

The Agreement includes customary events of default upon the occurrence of enumerated events, including non-payment of Revenue Interests, failure to perform certain covenants and the occurrence of insolvency proceedings, certain judgments, certain cross-defaults or certain revocations, withdrawals or cancellations of regulatory approval for selinexor. Upon the occurrence of an event of default, the Investors may accelerate payments due under the Agreement up to the Hard Cap. Upon the occurrence of certain material adverse events or the material breach of certain representations and warranties, which will not be considered events of default, the Investors may elect to terminate the Agreement and require the Company to make payments necessary for the Investors to receive the Investment Amount plus a specified annual rate of return. The Company’s obligations under the Agreement will be secured by a first priority perfected security interest in all present and future assets of the Company and its subsidiaries relating to selinexor.

In addition, the Agreement contains various representations and warranties, information rights, non-financial covenants, indemnification obligations and other provisions that are customary for a transaction of this nature. The closing of the transaction contemplated by the Agreement is subject to certain conditions that are customary for a transaction of this nature.

The Company expects to file the Agreement as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending September 30, 2019. The foregoing description of the Agreement is qualified in its entirety by reference to the text of the Agreement when filed.

A copy of the Company’s press release announcing the entry into the Agreement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01.    Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Number

   

Description of Exhibit

         
 

99.1

   

Press release issued by Karyopharm Therapeutics Inc. on September 16, 2019

         
 

104

   

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

KARYOPHARM THERAPEUTICS INC.

             

Date: September 16, 2019

 

 

By:

 

/s/ Christopher B. Primiano

 

 

 

Christopher B. Primiano

 

 

 

Executive Vice President, Chief Business Officer, General Counsel and Secretary

EX-99.1 2 d804595dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO    Targeting Disease at the Nuclear Pore

Karyopharm Enters Into Royalty Agreement with

Healthcare Royalty Partners for up to $150 Million

– Investment Expected to Extend Karyopharm’s Cash Runway into Middle of 2021 –

NEWTON, Mass. – September 16, 2019 – Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced its entry into a royalty agreement with HealthCare Royalty Partners (HCR) for up to $150 million to support the ongoing development and commercialization of XPOVIOTM (selinexor), the Company’s first-in-class, oral SINE compound, which is currently marketed in the U.S. for the treatment of patients with heavily pretreated multiple myeloma. Selinexor is also in late-stage clinical development for the treatment of patients with relapsed or refractory multiple myeloma who have had one to three prior lines of therapy and for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Under the terms of the agreement, Karyopharm will receive $75 million at closing this month and is eligible to receive an additional $75 million upon the achievement of future regulatory and commercial milestones and subject to approval by both parties. In exchange for the amount received at the initial closing, HCR will receive a tiered royalty in the mid-single digits based on worldwide net revenues of XPOVIO and any other future products. Karyopharm expects that the $75 million initially received from HCR under this royalty agreement, combined with its existing cash, cash equivalents and investments, together with the cash expected to be generated from product sales, will be sufficient to fund its operations into the middle of 2021.

“This non-dilutive financing provides Karyopharm with immediate and substantial capital to support the ongoing commercialization of XPOVIO in patients with heavily pretreated multiple myeloma, and further the development of selinexor in future high unmet need indications,” said Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm. “We are delighted to have the support and confidence of HealthCare Royalty Partners, a premier partner known for its strategic investments in promising healthcare companies and assets.”

Clarke Futch, Managing Partner and Chairman of the Investment Committee of HealthCare Royalty Partners stated: “Based on our extensive due diligence, we believe XPOVIO’s strong commercial prospects and upside potential creates an attractive investment profile for HCR. The Karyopharm leadership team has deep expertise in bringing innovative drugs to market for the treatment of high unmet need cancers, and we are pleased to be partnering with them during this transformative time in the Company’s evolution.”

XPOVIO received accelerated approval from the U.S. Food and Drug Administration (FDA) on July 3, 2019 for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. A Marketing Authorization Application (MAA) seeking conditional approval for selinexor is currently under review by the European Medicines Agency and Karyopharm expects to receive a decision on the MAA by early 2020.

Morgan Stanley & Co. LLC acted as sole structuring agent, and Goodwin Procter LLP acted as special transaction counsel, to Karyopharm on the transaction.

 

1

LOGO    Targeting Disease at the Nuclear Pore

 

About XPOVIO™ (selinexor)

XPOVIO is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein exportin 1 (XPO1, also called CRM1). XPOVIO blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. The forced nuclear retention of these proteins can counteract a multitude of the oncogenic pathways that, unchecked, allow cancer cells with severe DNA damage to continue to grow and divide in an unrestrained fashion. In addition to receiving accelerated FDA approval of XPOVIO in July 2019 in combination with dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody, Karyopharm has also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) with a request for conditional approval of selinexor. Selinexor is also being studied in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). In 2018, Karyopharm reported positive top-line results from the Phase 2b SADAL study evaluating selinexor in patients with relapsed or refractory DLBCL after at least two prior multi-agent therapies and who are ineligible for transplantation, including high dose chemotherapy with stem cell rescue. Selinexor has received Fast Track designation from the FDA for the patient population evaluated in the SADAL study. Selinexor is also being evaluated in several other mid-and later-phase clinical trials across multiple cancer indications, including in multiple myeloma in a pivotal, randomized Phase 3 study in combination with Velcade® (bortezomib) and low-dose dexamethasone (BOSTON), as a potential backbone therapy in combination with approved therapies (STOMP), in liposarcoma (SEAL), in recurrent gliomas (KING) and in endometrial cancer (SIENDO), among others. Additional Phase 1, Phase 2 and Phase 3 studies are ongoing or currently planned, including multiple studies in combination with approved therapies in a variety of tumor types to further inform Karyopharm’s clinical development priorities for selinexor. Additional clinical trial information for selinexor is available at www.clinicaltrials.gov.

Please see XPOVIO Full Prescribing Information available at www.XPOVIO.com.

About HealthCare Royalty Partners

HealthCare Royalty Partners (“HCR”) is a private investment firm that purchases royalties and uses debt-like structures to invest in commercial or near-commercial stage life science assets. HCR has $4.7 billion in cumulative capital commitments with offices in Stamford (CT), San Francisco, Boston and London. For more information, visit www.healthcareroyalty.com.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm’s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.

 

2

LOGO    Targeting Disease at the Nuclear Pore

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding our expectations relating to the anticipated use of proceeds from, and the financial and other benefits of, the royalty agreement with HCR, Karyopharm’s financial outlook and projections, the potential receipt of an additional $75 million under the royalty agreement upon the achievement of future regulatory and commercial milestones and subject to approval by both parties, continued commercialization of XPOVIO or commercialization of any of our drug candidates, the review and potential approval of selinexor by regulatory authorities, including the anticipated timing of actions and the potential availability of accelerated approval pathways, and the therapeutic potential of and potential clinical development plans for Karyopharm’s drug candidates, especially selinexor. Such statements are subject to numerous important factors, risks and uncertainties, many of which are beyond Karyopharm’s control, that may cause actual events or results to differ materially from Karyopharm’s current expectations. For example, there can be no guarantee that regulators will agree that selinexor qualifies for conditional approval in the E.U. as a result of the data from the STORM study or accelerated or conditional approval in the U.S. or EU, respectively, based on data from the SADAL study in patients with relapsed or refractory DLBCL, or that any of Karyopharm’s drug candidates, including selinexor, will successfully complete necessary clinical development phases or that development of any of Karyopharm’s drug candidates will continue. Further, there can be no guarantee that any positive developments in Karyopharm’s drug candidate portfolio will result in stock price appreciation. Finally, an additional $75 million may not be funded under the royalty agreement. Management’s expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the ability of Karyopharm and HCR to perform their respective obligations under the royalty agreement, the timing and costs involved in commercializing XPOVIO or any of Karyopharm’s drug candidates that receive regulatory approval; the ability to retain regulatory approval of XPOVIO or any of Karyopharm’s drug candidates that receive regulatory approval; Karyopharm’s results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, including with respect to the need for additional clinical studies; Karyopharm’s ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials; unplanned cash requirements and expenditures; development of drug candidates by Karyopharm’s competitors for diseases in which Karyopharm is currently developing its drug candidates; and Karyopharm’s ability to obtain, maintain and enforce patent and other intellectual property protection for any drug candidates it is developing. These and other risks are described under the caption “Risk Factors” in Karyopharm’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, which was filed with the Securities and Exchange Commission (SEC) on August 7, 2019, and in other filings that Karyopharm may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by law, Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Velcade® is a registered trademark of Takeda Pharmaceutical Company Limited

 

3

LOGO    Targeting Disease at the Nuclear Pore

 

Contacts:

Investors:

Karyopharm Therapeutics Inc.

Ian Karp, Vice President, Investor and Public Relations

857-297-2241 | ikarp@karyopharm.com

Media:

FTI Consulting

Simona Kormanikova or Robert Stanislaro

212-850-5600 |Simona.Kormanikova@fticonsulting.com or robert.stanislaro@fticonsulting.com

 

4

EX-101.SCH 3 kpti-20190914.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 kpti-20190914_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 kpti-20190914_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g8045952.jpg GRAPHIC begin 644 g8045952.jpg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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 8 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 1 97 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d804595d8k.htm d804595dex991.htm kpti-20190914.xsd kpti-20190914_lab.xml kpti-20190914_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false ZIP 9 0001193125-19-245346-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-19-245346-xbrl.zip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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 d804595d8k_htm.xml IDEA: XBRL DOCUMENT 0001503802 2019-09-14 2019-09-14 false 0001503802 8-K 2019-09-14 Karyopharm Therapeutics Inc. DE 001-36167 26-3931704 85 Wells Avenue 2nd Floor Newton MA 02459 (617) 658-0600 false false false false Common Stock, $0.0001 par value KPTI NASDAQ false EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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etaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d804595d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d804595d8k.htm" ] }, "labelLink": { "local": [ "kpti-20190914_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "kpti-20190914_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "kpti-20190914.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "kpti", "nsuri": "http://www.karyopharm.com/20190914", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "body", "html" ], "baseRef": "d804595d8k.htm", "contextRef": "duration_2019-09-14_to_2019-09-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "body", "html" ], "baseRef": "d804595d8k.htm", "contextRef": "duration_2019-09-14_to_2019-09-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20190914/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 15 R1.htm IDEA: XBRL DOCUMENT v3.19.2
Document and Entity Information
Sep. 14, 2019
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001503802
Document Type 8-K
Document Period End Date Sep. 14, 2019
Entity Registrant Name Karyopharm Therapeutics Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-36167
Entity Tax Identification Number 26-3931704
Entity Address, Address Line One 85 Wells Avenue
Entity Address, Address Line Two 2nd Floor
Entity Address, City or Town Newton
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02459
City Area Code (617)
Local Phone Number 658-0600
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value
Trading Symbol KPTI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false